// App-Quantinova.ai

1644 : Routine Assessment of Patient Index Data 3 (RAPID3)-Defined Remission Is As Stringent As ACR/EULAR Boolean-Defined Remission in a Clinical Trial of Patients with Early Rheumatoid Arthritis Treated with Abatacept

Researchers

Presenter

  • Yusuf Yazici

Principal Investigators

  • E Alemao

  • Daniel E. Furst

Medical Centers

  • University of California Los Angeles - David Geffen School of Medicine, Los Angeles, CA

  • NYU Hospital for Joint Diseases, New York, NY

Locations

  • United States

Companies

  • Bristol-Myers Squibb

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • C reactive protein

  • High sensitivity C-reactive protein

  • Albumin/creatinine

Drug/Treatment

  • Abatacept

Outcome

  • N/A

Study Design

  • randomized

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved